Moleculin Biotech, Inc. (MBRX): Nasdaq/NYSE listing notice — Moleculin Biotech receives Nasdaq delisting notice for non-compliance with equity rule

Moleculin Biotech, Inc.

Received delist determination letter on Nov 20, 2025 for failing to meet $2.5M minimum stockholders' equity requirement.
Nasdaq will delist on Dec 2, 2025 unless Company requests a hearing panel appeal by Nov 28, 2025.
Moleculin intends to appeal the determination to stay suspension and continue trading under symbol MBRX.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Moleculin Biotech, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 20, 2025, the Company received a delist determination letter from the Staff (the “Nasdaq Notice”) advising the Company that the Staff had determined that the Company had not regained compliance with the Listing Rule. Accordingly, the Staff indicated that unless the Company requests a hearing panel (a “Panel”) appeal of the delist determination by November 28, 2025, its securities would be delisted on December 2, 2025. The Company intends to appeal Nasdaq’s determination to a Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series to stay any suspension pendin

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-036006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.